Alvotech and Advanz Pharma secure EC authorisation for treatment of immune-mediated diseases

New patent strengthens IP position for treatment of influenza side effects

Protara’s phase 2 STARBORN-1 study reports high response rates and no serious adverse events

New authorisation marks major milestone in earlier treatment of skin cancer

Munich-based start-up backed by Frontline Ventures and Y Combinator eyes global expansion

Six new Grand Challenges aim to tackle drug resistance and accelerate antibiotic discovery

New ONE BioHub facility expands clinical trial access and strengthens Scotland’s brain health innovation

New treatment option for spinal muscular atrophy moves closer to EU approval

48-month analysis shows delayed progression and reduced risk in early Alzheimer’s patients

AI platform to support biomarker-guided therapy development in MASH